57 related articles for article (PubMed ID: 38481326)
1. Sialic acid-modified doxorubicin liposomes target tumor-related immune cells to relieve multiple inhibitions of CD8
Du Z; Sui D; Xin D; Tang X; Li M; Liu X; Deng Y; Song Y
J Liposome Res; 2024 Sep; 34(3):464-474. PubMed ID: 38196168
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of Smac mimetic APG-1387 with anti-PD-1 antibody are attributed to increased CD3 + NK1.1 + cell recruitment secondary to induction of cytokines from tumor cells.
Pan W; Luo Q; Liang E; Shi M; Sun J; Shen H; Lu Z; Zhang L; Yan X; Yuan L; Zhou S; Yi H; Zhai Y; Qiu MZ; Yang D
Cancer Cell Int; 2024 May; 24(1):181. PubMed ID: 38790057
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of doxorubicin-dihydroartemisinin prodrug/TEPP-46 nano-liposomes for improving antitumor and decreasing cardiotoxicity in B16-F10 tumor-bearing mice.
Jin Q; Zhou X; Niu X; Ping C; Dong X; Duan D; Wang R; Chen Y; Pan F; Yang F; Yang X; Zhang G; Wang R; Zhang S; Ren G
Colloids Surf B Biointerfaces; 2024 May; 241():113992. PubMed ID: 38833960
[TBL] [Abstract][Full Text] [Related]
4. Regulation of CTLs/Tregs via Highly Stable and Ultrasound-Responsive Cerasomal Nano-Modulators for Enhanced Colorectal Cancer Immunotherapy.
Zhang J; Sun L; Jiang L; Xie X; Wang Y; Wu R; Tang Q; Sun S; Zhu S; Liang X; Cui L
Adv Sci (Weinh); 2024 Jun; 11(22):e2400485. PubMed ID: 38552151
[TBL] [Abstract][Full Text] [Related]
5. A Tumor-Specific Cascade-Activating Smart Prodrug System for Enhanced Targeted Therapy.
Wang Q; Jin D; Liu C; Shi L; Li T
Small; 2024 Jun; 20(24):e2309482. PubMed ID: 38150668
[TBL] [Abstract][Full Text] [Related]
6. Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy.
Yang Y; Wang Y; Zeng F; Chen Y; Chen Z; Yan F
Cell Rep Med; 2024 May; 5(5):101512. PubMed ID: 38640931
[TBL] [Abstract][Full Text] [Related]
7. High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles.
Au KM; Balhorn R; Balhorn MC; Park SI; Wang AZ
ACS Cent Sci; 2019 Jan; 5(1):122-144. PubMed ID: 30693332
[TBL] [Abstract][Full Text] [Related]
8. Adhesion between EVs and tumor cells facilitated EV-encapsulated doxorubicin delivery via ICAM1.
Wang S; Qiao C; Kong X; Yang J; Guo F; Chen J; Wang W; Zhang B; Xiu H; He Y; Wang J; Feng H; Cai Z
Pharmacol Res; 2024 May; 205():107244. PubMed ID: 38821149
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin induces deglycosylation of cancer cell-intrinsic PD-1 by NGLY1.
Wu D; Wu Z; Yao H; Yan X; Jiao Z; Liu Y; Zhang M; Wang D
FEBS Lett; 2024 May; ():. PubMed ID: 38782868
[TBL] [Abstract][Full Text] [Related]
10. Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade.
Zhou F; Feng B; Yu H; Wang D; Wang T; Ma Y; Wang S; Li Y
Adv Mater; 2019 Apr; 31(14):e1805888. PubMed ID: 30762908
[TBL] [Abstract][Full Text] [Related]
11. Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery.
Kyu Shim M; Yang S; Sun IC; Kim K
Adv Drug Deliv Rev; 2022 Apr; 183():114177. PubMed ID: 35245568
[TBL] [Abstract][Full Text] [Related]
12. Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy.
Kim J; Shim MK; Moon Y; Kim J; Cho H; Yun WS; Shim N; Seong JK; Lee Y; Lim DK; Kim K
J Nanobiotechnology; 2024 Mar; 22(1):109. PubMed ID: 38481326
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
14. Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy.
Choi J; Shim MK; Yang S; Hwang HS; Cho H; Kim J; Yun WS; Moon Y; Kim J; Yoon HY; Kim K
ACS Nano; 2021 Jul; 15(7):12086-12098. PubMed ID: 34165970
[TBL] [Abstract][Full Text] [Related]
15. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
